Adial Pharmaceuticals Regains Compliance with Nasdaq Stockholders’ Equity Listing Requirement
Adial Pharmaceuticals (NASDAQ: ADIL), a clinical-stage biopharmaceutical company focused on addiction treatment therapies, has successfully regained compliance with Nasdaq's listing requirements. The company received notice from Nasdaq on July 14, 2025 confirming its compliance with Rule 5550(b)(1), which mandates maintaining stockholders' equity of at least $2.5 million.
CEO Cary Claiborne emphasized this achievement as a crucial step in strengthening investor confidence and supporting the company's long-term growth strategy, while highlighting their commitment to disciplined financial management and pipeline advancement.
Adial Pharmaceuticals (NASDAQ: ADIL), un'azienda biofarmaceutica in fase clinica specializzata in terapie per il trattamento delle dipendenze, ha riconquistato con successo la conformità ai requisiti di quotazione del Nasdaq. La società ha ricevuto il 14 luglio 2025 una comunicazione dal Nasdaq che conferma il rispetto della Regola 5550(b)(1), che richiede un patrimonio netto degli azionisti di almeno 2,5 milioni di dollari.
Il CEO Cary Claiborne ha sottolineato che questo risultato rappresenta un passo fondamentale per rafforzare la fiducia degli investitori e sostenere la strategia di crescita a lungo termine dell'azienda, evidenziando al contempo il loro impegno nella gestione finanziaria disciplinata e nello sviluppo del portafoglio prodotti.
Adial Pharmaceuticals (NASDAQ: ADIL), una compañía biofarmacéutica en etapa clínica enfocada en terapias para el tratamiento de adicciones, ha recuperado exitosamente el cumplimiento de los requisitos de listado de Nasdaq. La empresa recibió una notificación de Nasdaq el 14 de julio de 2025 confirmando su cumplimiento con la Regla 5550(b)(1), que exige mantener un patrimonio neto de al menos 2.5 millones de dólares.
El CEO Cary Claiborne destacó este logro como un paso crucial para fortalecer la confianza de los inversores y apoyar la estrategia de crecimiento a largo plazo de la compañía, resaltando su compromiso con una gestión financiera disciplinada y el avance en su cartera de productos.
Adial Pharmaceuticals (NASDAQ: ADIL)은 중독 치료제에 중점을 둔 임상 단계 바이오제약 회사로, 나스닥 상장 요건을 성공적으로 충족하였습니다. 회사는 2025년 7월 14일 나스닥으로부터 주주 자본금이 최소 250만 달러 이상이어야 한다는 규칙 5550(b)(1) 준수를 확인하는 통지를 받았습니다.
CEO 캐리 클레이본은 이 성과가 투자자 신뢰를 강화하고 회사의 장기 성장 전략을 지원하는 중요한 단계임을 강조하며, 엄격한 재무 관리와 파이프라인 개발에 대한 의지를 나타냈습니다.
Adial Pharmaceuticals (NASDAQ : ADIL), une société biopharmaceutique en phase clinique spécialisée dans les thérapies de traitement de la dépendance, a réussi à se conformer de nouveau aux exigences de cotation du Nasdaq. La société a reçu un avis du Nasdaq le 14 juillet 2025 confirmant sa conformité à la règle 5550(b)(1), qui exige de maintenir un fonds propres d'au moins 2,5 millions de dollars.
Le PDG Cary Claiborne a souligné que cette réussite constitue une étape cruciale pour renforcer la confiance des investisseurs et soutenir la stratégie de croissance à long terme de l'entreprise, tout en mettant en avant leur engagement envers une gestion financière rigoureuse et le développement de leur pipeline de produits.
Adial Pharmaceuticals (NASDAQ: ADIL), ein biopharmazeutisches Unternehmen in der klinischen Phase mit Fokus auf Therapien zur Behandlung von Suchterkrankungen, hat erfolgreich die Einhaltung der Nasdaq-Listing-Anforderungen wiedererlangt. Das Unternehmen erhielt am 14. Juli 2025 eine Mitteilung von Nasdaq, die die Einhaltung der Regel 5550(b)(1) bestätigt, welche ein Eigenkapital von mindestens 2,5 Millionen US-Dollar vorschreibt.
CEO Cary Claiborne betonte, dass dieser Erfolg ein entscheidender Schritt zur Stärkung des Anlegervertrauens und zur Unterstützung der langfristigen Wachstumsstrategie des Unternehmens sei, und hob dabei das Engagement für diszipliniertes Finanzmanagement und die Weiterentwicklung der Produktpipeline hervor.
- Regained compliance with Nasdaq listing requirements by maintaining stockholders' equity above $2.5 million
- Company maintains listing on major exchange, ensuring continued access to capital markets
- Previous non-compliance with Nasdaq requirements indicates recent financial challenges
GLEN ALLEN, Va., July 16, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that it received notice from Nasdaq on July 14, 2025 that the Company has regained compliance with Nasdaq Listing Rule 5550(b)(1), which requires listed companies to maintain stockholders' equity of at least
Cary Claiborne, President and Chief Executive Officer of Adial, commented, “We’re pleased to have regained compliance with Nasdaq, a key step in reinforcing investor confidence and supporting our long-term growth strategy. This reflects our commitment to disciplined financial management as we continue advancing our pipeline and creating value for shareholders.”
About Adial Pharmaceuticals, Inc.
Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of treatments for addictions and related disorders. The Company’s lead investigational new drug product, AD04, is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) in heavy drinking patients and was recently investigated in the Company’s ONWARD™ pivotal Phase 3 clinical trial for the potential treatment of AUD in subjects with certain target genotypes identified using the Company’s companion diagnostic genetic test. ONWARD showed promising results in reducing drinking in heavy drinking patients, and no overt safety or tolerability concerns. AD04 is also believed to have the potential to treat other addictive disorders such as Opioid Use Disorder, gambling, and obesity. Additional information is available at www.adial.com.
Forward-Looking Statements
This communication contains certain “forward-looking statements” within the meaning of the U.S. federal securities laws. Such statements are based upon various facts and derived utilizing numerous important assumptions and are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Statements preceded by, followed by or that otherwise include the words “believes,” “expects,” “anticipates,” “intends,” “projects,” “estimates,” “plans” and similar expressions or future or conditional verbs such as “will,” “should,” “would,” “may” and “could” are generally forward-looking in nature and not historical facts, although not all forward-looking statements include the foregoing. The forward-looking statements include statements regarding reinforcing investor confidence and supporting our long-term growth strategy, the commitment to disciplined financial management, continuing to advance the Company’s pipeline and creating value for shareholders and the potential of AD04 to treat other addictive disorders such as Opioid Use Disorder, gambling, and obesity. Any forward-looking statements included herein reflect our current views, and they involve certain risks and uncertainties, including, among others, our ability to obtain regulatory approvals for commercialization of product candidates or to comply with ongoing regulatory requirements, our ability to develop strategic partnership opportunities and maintain collaborations, our ability to obtain or maintain the capital or grants necessary to fund our research and development activities, our ability to complete clinical trials on time and achieve desired results and benefits as expected, regulatory limitations relating to our ability to promote or commercialize our product candidates for specific indications, acceptance of our product candidates in the marketplace and the successful development, marketing or sale of our products, our ability to maintain our license agreements, the continued maintenance and growth of our patent estate and our ability to retain our key employees or maintain our Nasdaq listing. These risks should not be construed as exhaustive and should be read together with the other cautionary statement included in our Annual Report on Form 10-K for the year ended December 31, 2024, subsequent Quarterly Reports on Form 10-Q and current reports on Form 8-K filed with the Securities and Exchange Commission. Any forward-looking statement speaks only as of the date on which it was initially made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, changed circumstances or otherwise, unless required by law.
Contact:
Crescendo Communications, LLC
David Waldman / Alexandra Schilt
Tel: 212-671-1020
Email: adil@crescendo-ir.com
FAQ
What Nasdaq compliance requirement did Adial Pharmaceuticals (ADIL) meet in July 2025?
When did Adial Pharmaceuticals (ADIL) receive notice of Nasdaq compliance?
What is the minimum stockholders' equity required for Nasdaq listing under Rule 5550(b)(1)?
Who is the CEO of Adial Pharmaceuticals (ADIL) in 2025?
What is Adial Pharmaceuticals' (ADIL) main business focus?
